These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25604780)

  • 1. Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance.
    Kolovou G; Vasiliadis I; Gontoras N; Kolovou V; Hatzigeorgiou G
    Cardiovasc Ther; 2015 Apr; 33(2):71-8. PubMed ID: 25604780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
    Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
    Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.
    Vuorio A; Tikkanen MJ; Kovanen PT
    Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia.
    Raper A; Kolansky DM; Sachais BS; Meagher EA; Baer AL; Cuchel M
    J Clin Lipidol; 2015; 9(1):107-12. PubMed ID: 25670368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lomitapide.
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):347-52. PubMed ID: 21846156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia.
    Walsh MT; Hussain MM
    Crit Rev Clin Lab Sci; 2017 Jan; 54(1):26-48. PubMed ID: 27690713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lomitapide for the management of homozygous familial hypercholesterolemia.
    deGoma EM
    Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.
    Toth PP; Shah PK; Wilkinson MJ; Davidson MH; McCullough PA
    Rev Cardiovasc Med; 2014; 15(1):1-10. PubMed ID: 24762461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.
    Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
    Eur J Prev Cardiol; 2017 May; 24(8):867-875. PubMed ID: 28186442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
    Marbach JA; McKeon JL; Ross JL; Duffy D
    Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
    Cuchel M; Blom DJ; Averna MR
    Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia.
    Sirtori CR; Pavanello C; Bertolini S
    Ann Med; 2014 Nov; 46(7):464-74. PubMed ID: 24987866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
    Stefanutti C
    Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsomal transfer protein inhibition in humans.
    Cuchel M; Rader DJ
    Curr Opin Lipidol; 2013 Jun; 24(3):246-50. PubMed ID: 23594709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
    Perry CM
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia.
    Rizzo M
    IDrugs; 2010 Feb; 13(2):103-11. PubMed ID: 20127562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
    Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
    Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.